Evolving Treatment Landscape in Multiple Myeloma
The multiple myeloma (MM) treatment landscape is undergoing a major shift, driven by the rise of BCMA-targeted therapies, expanded use of Darzalex-based regimens, and next-generation immunomodulatory drugs. With incident cases projected to rise significantly across the US, EU5, and Japan by 2043, the market is expected to grow from $28.4B in 2024 to $59.2B by 2034.
Checkpoint inhibitors are not the dominant force in MM, but CD38-targeting monoclonal antibodies like Darzalex have become the backbone of frontline and relapsed/refractory regimens. BCMA-targeted therapies—including Carvykti, Abecma, Tecvayli, and Elrexfio—are reshaping treatment paradigms, with label expansions into earlier lines of therapy expected to drive significant commercial growth.
Meanwhile, next-generation IMiDs such as iberdomide and mezigdomide are poised to replace legacy agents like Revlimid and Pomalyst, which are facing generic erosion. In the relapsed/refractory setting, bispecific antibodies and CAR-T therapies are gaining traction, though logistical challenges remain.
In this report we cover:
- Key growth drivers: BCMA-targeted therapies, Darzalex-based quadruplets, and rising incident cases in the US, EU5, and Japan.
- Promising therapies: Carvykti, Tecvayli, Elrexfio, and Darzalex combinations across lines of therapy.
- Novel modalities: CAR-T, bispecific antibodies, and next-gen IMiDs like iberdomide and mezigdomide.
